I went back to the diabetes clinic for my first follow up since going on the pump. I met with the diabetes nurse and nutritionist. They were both very…
The choice is yours. You can be clean about your diabetes, or you can be a diabetes slob. That’s vague, I know, so let me put it into specifics. …
I’ll start with the bottom line. I chose the Medtronic Minimed Paradigm VEO. The VEO, which is marketed outside the U.S (Europe, Canada….) is basically…
By taking the science from the world of the researchers and doctors into the world of the patient, we remove some of the alienation from our own bodies...
XOMA announced the first presentation of results from its discovery of two new classes of fully human monoclonal antibodies that activate or sensitize the insulin receptor in vivo, each representing a distinct new therapeutic approach to the treatment of patients with diabetes. The data were presented at the American Diabetes Association 71st Scientific Sessions in San Diego...
Tell me that an old tuberculosis drug might be able to reverse Type 1 diabetes, and I’ll have the following reaction: a moment of excitement,…
New data from two extension studies presented by Novo Nordisk at the 71st Annual Scientific Sessions of the American Diabetes Association (ADA) show that Victoza (liraglutide [rDNA origin] injection), taken once-daily, in combination with metformin and/or sulfonylurea, helped patients achieve blood sugar control after switching from other commonly used type 2 diabetes therapies Byetta (exenatide) and Januvia (sitagliptin). Although not..
New data from two previously completed clinical studies show that Symlin (pramlintide acetate) helped reduce A1c levels, insulin use and body weight in patients with type 1 diabetes who used insulin pumps. The data was presented by Amylin Pharmaceuticals during...
Results from a retrospective analysis of more than 778,000 patients showed the addition of Byetta (exenatide) injection to pre-existing diabetes treatment regimens was associated with a reduced likelihood of heart failure, especially among patients receiving insulin. These findings were presented by Amylin and Eli Lilly...
Amylin, Eli Lilly and Alkermes, announced results from long-term extensions of the DURATION-1 and 3 studies evaluating Bydureon (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes. The studies will be presented at the...